Additionally, the toxicity of other EGFR targeted therapies such as erlotinib and gefitinib is related to signal-triggering and tyrosine kinase inhibition resulting in xerosis, pruritus, alopecia, and hand and foot reactions, among others [32,33]. Here, EGFR is linked to alopecia.